Reg Snafu Drives Boston Scientific CDS Wide
The cost of insuring Boston Scientific Corp. debt against default widened 20 basis points, or nearly 13%, from last night’s close after the medical device maker admitted it had neglected to seek regulatory approval for a change in its manufacturing process.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
